Movers: Genzyme, Target, Microsoft, CBOT

Friday's stocks in the news

Genzyme (GENZ) falls after it announces that tolevamer liquid, its experimental therapy for patients with diarrhea linked to a severe bacteria, failed to meet main goal of a Phase 3 study. S&P reiterates strong buy on the stock.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.